Trials / Unknown
UnknownNCT02825394
Specific PoC Testing of Coagulation in Patients Treated With DOAC 1
Specific Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants Part 1
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 160 (estimated)
- Sponsor
- University Hospital Tuebingen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators study aims to test the correlation between the Cascade Abrazo point-of-care testing (POCT) device (Helena Laboratories, USA) and plasma levels of apixaban, dabigatran, edoxaban and rivaroxaban, and to determine the diagnostic accuracy of POCT to rule out or detect relevant levels of direct oral anticoagulants (DOAC) in real-life patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | anti-Xa activity point-of-care testing (aXa-POCT) | |
| OTHER | ecarin clotting time point-of-care testing (ECT-POCT) |
Timeline
- Start date
- 2016-10-13
- Primary completion
- 2021-03-01
- Completion
- 2021-07-01
- First posted
- 2016-07-07
- Last updated
- 2020-12-16
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02825394. Inclusion in this directory is not an endorsement.